4Han S B.Current therapy of hepatitis B[C].61st AASLD Postgraduate Course,2010:36-43.
5Hoofnagle J H.Therapy of hepatitis B:unresolved issues and remaining challenges[C].61st AASLD Postgraduate Course,2010:52-55.
6European Association for the study of the liver.EASL clinical practice guidelines:management of chrotitis B[J].J Hepatol,2009,50:227-242.
7Mao Y,Zeng M,Yao G,et al.Efficacy and safety of 4 years adefovir dipivoxil 10 mg (ADV) in chinese HbeAg+ve chronic hepatitis B(CHB)[J].Hepatol Int,2008,2(1):98.
8Ghany M G.Drug resistance in antiviral therapy of hepatitis B[C].61st AASLD Postgraduate Course,2010:44-51.
9Liaw Y F.Meet-the-professor luncheon,HBV therapy:practice[C].61st AASLD Postgraduate Course,2010:60-70.
7Liver Failure and Artificial Liver Group, Chinese Society of Infectious Diseases, Chinese Medical Association.肝衰竭诊疗指南[J].中华肝脏病杂志,2006,14(9):643-646. 被引量：829
2Chinese Society of Hepatology and Chinese Society of Infectious Diseases,Chinese Medical Association. 42 Dongsi Xidajie,Beijing 100710,China.慢性乙型肝炎防治指南[J].中华肝脏病杂志,2005,13(12):881-891. 被引量：1931
9Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survivalin patients with end-stage liverdisease. Hepatology, 2001, 33 : 464-470.
10Nishlmura A ,Umehara Y ,Urn ehara M , et al. Plasma exchange based plasma recycling dialysis system as a potential platform for artificial liver support. Artif Organs. 2006,30:629-633.
